Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
touchEXPERT OPINIONS for touchONCOLOGY
Listen to three leading experts sharing their perspectives on the impact of the 2022 guideline updates on diagnosis, classification and management of higher-risk myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML).
The experts:
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Novartis and is provided by touchIME.
For further information visit: www.touchoncology.com/education/impact-of-new-guidelines-in-MDS-AML
Create your
podcast in
minutes
It is Free